Biogen to Acquire Apellis for $5.6B Cash Plus CVRs, Boosting Immunology & Rare Disease Portfolio

summarizeSummary

Biogen announced a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash plus contingent value rights, significantly expanding its immunology and rare disease portfolio.

check_boxKey Events

• Acquisition Agreement

  Biogen will acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash upfront through a tender offer, followed by a second-step merger.

• Contingent Value Rights (CVRs)

  Apellis stockholders will receive one non-transferable CVR per share, potentially worth up to an aggregate of $4.00 in cash, contingent on SYFOVRE® annual global net sales milestones ($1.5B and $2.0B) through 2031.

• Strategic Expansion

  The acquisition adds two commercialized immunology and rare disease products, EMPAVELI® and SYFOVRE®, to Biogen's portfolio, with combined 2025 net sales of $689 million, expected to grow at a mid-to-high teens rate through at least 2028.

• Financial Impact

  The transaction is expected to be increasingly accretive to Biogen's non-GAAP diluted EPS starting in 2027 and significantly boost its non-GAAP EPS compounded annual growth rate through the end of the decade.

auto_awesomeAnalysis

This 8-K details Biogen's definitive agreement to acquire Apellis Pharmaceuticals, a significant strategic move valued at approximately $5.6 billion upfront, plus potential contingent value rights (CVRs) of up to $4.00 per share based on SYFOVRE® net sales milestones. The acquisition is expected to immediately enhance Biogen's growth profile by adding two commercialized immunology and rare disease medicines, EMPAVELI® and SYFOVRE®, which generated $689 million in combined net sales in 2025. This transaction is projected to be increasingly accretive to Biogen's non-GAAP diluted EPS starting in 2027 and accelerate its expansion into nephrology. The support from key Apellis insiders, who have agreed to tender their 14% stake, underscores confidence in the deal. Investors should monitor the integration process and the performance of the acquired assets, particularly SYFOVRE® sales, which will determine the CVR payouts.